MATINAS BIOPHARMA HOLDINGS I (MTNB)
US5768101058 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 4.79M | 6.83M | 21.03M | 12.43M | 22.17M | |||
| Marketable Securities | 8.97M | 21.93M | 28.59M | 46.25M | 5.60M | |||
| Other Current Assets | 1.79M | 5.77M | 1.37M | 2.88M | 2.15M | |||
| Total Current Assets | 15.54M | 34.53M | 50.99M | 61.55M | 29.92M | |||
| Non-Current Assets | ||||||||
| PPE Net | 5.01M | 5.73M | 5.78M | 4.86M | 5.63M | |||
| Goodwill | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | |||
| Intangibles | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | |||
| Other Non-Current Assets | 200.00K | 200.00K | 200.00K | 200.00K | 336.00K | |||
| Total Non-Current Assets | 9.56M | 10.29M | 10.33M | 9.41M | 10.32M | |||
| TOTAL ASSETS | 25.10M | 44.82M | 61.33M | 70.97M | 40.24M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 5.00K | 7.00K | 21.04K | 30.85K | 54.67K | |||
| Accrued Expenses | 2.10M | 2.94M | 2.46M | 2.54M | 2.26M | |||
| Accounts Payable | 514.00K | 618.00K | 938.27K | 349.94K | 679.31K | |||
| Other Current Liabilities | 0.00 | 721.00K | 932.00K | 643.00K | 100.00K | |||
| Total Current Liabilities | 2.62M | 4.29M | 4.35M | 3.57M | 3.10M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 18.00K | 22.00K | 2.62K | 23.66K | 54.51K | |||
| Deferred Taxes/Income | 341.00K | 341.00K | 341.27K | 341.27K | 341.27K | |||
| Other Non-Current Liabilities | 2.88M | 3.53M | 4.14M | 3.30M | 3.70M | |||
| Total Non-Current Liabilities | 3.24M | 3.90M | 4.48M | 3.67M | 4.09M | |||
| TOTAL LIABILITIES | 5.86M | 8.18M | 8.83M | 7.24M | 7.19M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -175.57M | -152.63M | -131.63M | -107.51M | -84.38M | |||
| Additional Paid In Capital | 195.02M | 190.07M | 184.25M | 167.19M | 113.43M | |||
| Common Shares | 22.00K | 22.00K | 21.63K | 3.82M | 4.00M | |||
| Other Shareholders' Equity | N/A | N/A | N/A | 228.17K | -880.00 | |||
| Shares Outstanding | 217.26M | 217.26M | 216.27M | 200.11M | 163.16M | |||
| Tangible Book Value per Share | 0.07 | 0.15 | 0.22 | 0.28 | 0.15 | |||
| Total Shareholders' Equity | 19.25M | 36.64M | 52.49M | 63.73M | 33.05M | |||
| TOTAL LIABILITIES AND EQUITY | 25.10M | 44.82M | 61.33M | 70.97M | 40.24M | |||
| Statistics | ||||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Ratio | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | |||
| Return On Assets (ROA) | -91.39% | -46.85% | -38.61% | -32.75% | -45.47% | |||
| Return On Equity (ROE) | -119.20% | -57.31% | -45.11% | -36.47% | -55.36% | |||
All data in USD